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Cost-effectiveness analysis (CEA) is taken to mean comparing the 
costs of different interventions against each ‘unit of gain’ (such as 
a life saved or disability averted) – it identifies which intervention 
provides the ‘best value for money’. A key assumption is that, if 
employed in South Africa, CEA should support the achievement of 
equity and strengthen the district health system. Some examples are 
provided in the main text; a complete list appears in Appendix A.
Setting priorities at the level of the 
patient
At the level of the patient, CEA helps to decide which of several 
alternative interventions is the most cost-effective in addressing a specific 
problem. A study in KwaZulu-Natal found that replacing monotherapy 
for malaria with dual therapy led to a decline in outpatient cases and 
inpatient admissions by a third and half, respectively.1 Although dual 
therapy was considerably more expensive, its better cure rate led to 
large savings. CEA is also used to distinguish which patients with a 
specific condition will benefit most from a specific intervention. A Cape 
Town study concluded that initiating highly active antiretroviral 
therapy (ART) before a patient’s CD4 count falls to 200/µl is more 
cost-effective: early therapy provides significant clinical benefits, even 
though the total cost of treatment is less when it commences below a 
CD4 count of 200.2 CEA can therefore encourage funders to invest in 
interventions that appear more costly (per patient treated) but lead to 
an overall reduction in the demands on the health service. 
As knowledge around the cost-effectiveness of interventions 
accumulates, it becomes incorporated into treatment protocols that 
guide clinicians in their practice. Treatment protocols are commonly 
used in the South African public sector and are reinforced by the 
Essential Drugs List, which constrains the options for treatment. In 
the private sector, treatment protocols also determine reimbursement 
patterns and authorisation for treatment for patients belonging to 
medical schemes. 
CEA therefore moves beyond affecting decisions around the 
different care options for an individual patient to influence the 
treatment patterns of providers.  This can enhance the equity and 
efficiency of the health system. A Mozambican study investigated the 
use of rapid diagnostic tests that are performed on people showing 
clinical signs of malaria to determine whether they are carrying 
the parasite. The test saves costs, as expensive antimalarial drugs 
(specifically artemisinin-based combination therapies) are only given 
to those suffering from the disease. However, the test itself costs 
money. The study found that it would be even more cost-saving to 
limit rapid diagnostic testing to patients older than 6 years and to 
treat all patients under 6 years old simply on the basis of clinical 
diagnosis. As children under 6 experience the most severe malaria, 
the authors felt that health care providers would, in any case, find it 
difficult to deny treatment to children who tested negative.3
CEA studies challenged South African hypertension treatment 
guidelines on the basis that, if applied uniformly to all patients, they 
would lead to some cost-ineffective treatment decisions, poorer 
health outcomes and wasted resources.4-5  It was found that the cost-
effectiveness of South African hypertension treatment guidelines is 
poor because the decision to treat is based only on a blood pressure 
above a target level. The flaw in this approach is that the combined 
impact of several risk factors is not taken into account (the ‘global’ 
risk): some people may fall above the blood pressure target but have a 
low global risk, while others may fall below the target and have a high 
global risk. The guidelines therefore lead to over-treatment of low-
risk people and under-treatment of high-risk people. Using a global 
risk approach would save considerable resources and improve health 
outcomes, demonstrating the value of including CEA in protocols 
that are based purely on epidemiological and effectiveness data. 
Setting priorities at the level of the 
service
CEAs can adjudicate between different modes of service delivery. A 
study on the outcomes and costs of tuberculosis (TB) treatment in 
Cape Town compared clinic-based care and observation with clinic-
based care supported by observation in the community by community 
health workers. The study included the costs faced by patients, rather 
than simply those incurred by the health service, and found that 
using community health workers improved the affordability and 
cost-effectiveness of treatment.6 This led directly to a national policy 
on the remuneration of community health workers.7 Such studies 
promote improved efficiency and contribute to equity by improving 
access and reducing the financial burden of care on households. 
Another study found that the ‘ProTEST package’ of combined TB 
and HIV interventions in the primary care setting in Cape Town 
saved costs.8 Preventing TB cost less than previous estimates because 
of the linkage of prevention and care interventions for both TB and 
HIV, showing the potential of CEA in encouraging the integration 
of services.
Achieving efficiency at the service level is of particular concern 
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Priority-setting in the health system is necessary because resources 
are constrained. The role of cost-effectiveness analysis in supporting 
decision-making around health care priorities in South Africa is 
explored by referring to South African studies that have provided 
clinical and policy guidance at the levels of the patient, the service 
and the population. Cost-effectiveness evidence is positioned 
in relation to other concerns such as equity and the overall 
performance of the health system. 
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central hospitals. In South Africa the development of CEA capacity to 
inform the use of expensive procedures, technologies and medicines 
is being debated.9-11 CEA could eliminate cost-ineffective diagnostic 
and therapeutic approaches and target rationed services towards 
patients most able to benefit from them. It could also suggest a shift 
in the configuration of services, promoting care at lower levels of the 
health system. An important finding of the second Disease Control 
Priorities for Developing Countries Project was that emergency (and 
even some elective) surgery and the resuscitation of newborns can be 
highly cost-effective and affordable when rendered at the district and 
even the community level. However, this depends on the use of mid-
level workers and simple technologies that would make such services 
more accessible than previously considered feasible.12-13
Setting priorities at the level of the 
population
Priority-setting at population level decides the relative importance 
of different health problems and whether – and how – they should 
be addressed. One instance of how CEA can assist is to identify 
interventions that need to be introduced to respond to emerging 
conditions. Often this process begins with identification of the health 
and economic burden of a condition. A study in South Africa in the 
late 1980s estimated the costs to the country of smoking, e.g. lost 
productivity due to premature death and the costs of health care.14 It 
found that these and future costs outweighed any economic benefit 
the industry may have brought to South Africa.
Once the burden has been established, follow-up studies estimate 
the cost-effectiveness of intervention strategies and sometimes move 
on to assessments of the affordability of interventions, including 
scaling up. A well-known instance of the use of CEA to this end in 
South Africa is the case of ART: CEAs, in tandem with estimates 
of the economic burden of the disease, built the case for treatment 
when government appeared resistant. Studies first demonstrated the 
cost-effectiveness of the prevention of mother-to-child transmission 
and the introduction of antiretrovirals to the general population, then 
investigated different options for delivery, and finally estimated the 
affordability of scaling up. The following are some examples of cost-
effectiveness studies on ART for HIV/AIDS in South Africa:
Estimates of the health and economic burden of HIV/AIDS. In 
the early 1990s, a study projected the future health and economic 
burden of HIV/AIDS.15 In 2000, a study projected the impact of HIV/
AIDS on the South African health sector.16
Cost-effectiveness analyses of prevention of mother-to-child 
transmission. It was estimated that a national programme preventing 
a third of expected paediatric HIV infections would be relatively 
cheap per capita and in terms of cost-effectiveness would compare 
well with other public health and clinical interventions in middle-
income countries.17 It was found that each HIV-positive child costs 
the South African government more in terms of health care and 
welfare than to reduce mother-to-child transmission of HIV through 
the use of nevirapine.18
Cost-effectiveness analyses of ART. Building on the projections 
of studies in the mid- and late 1990s, a detailed cost-effectiveness 
study confirmed that treatment is cost-effective.2 ART leads to overall 
health service savings as it reduces the need for clinical care; this cost 
saving increases as drug prices come down.19 A KwaZulu-Natal study 
of the cost of extending ART to health care workers motivated that 
these costs would be moderate and that benefits would be reduced 
absenteeism and alleviation of future staff shortages.20
Analyses of affordability. Following the introduction of ART 
in South Africa, the costs and cost-effectiveness of one of the 
longest-running public antiretroviral programmes in Africa, based 
in Khayelitsha, Cape Town, were studied. It provided data on the 
incremental costs and cost-effectiveness associated with scaling 
up services to assist in decisions around budget development and 
resource allocation.21 Escalating costs as patients move from first-
line to second-line treatment and the proportion of unmet need that 
could be met at different budget levels  were subsequently studied 
using a ‘health-maximising’ combination of different interventions 
(no ART, first-line ART and first- and second-line ART).22 
In the Western Cape perceptions at community, health service and 
policy level around the introduction of the human papillomavirus 
vaccine to prevent cervical cancer were studied.23 This, and a CEA 
(not yet published), led the Department of Health to consider 
introducing the vaccine into its immunisation programme.7 The 
cost-effectiveness study indicates the vaccine price at which it will 
become cost-effective to introduce the vaccine, which can assist the 
government in negotiating a reduced vaccine price.
CEA at the population level is also used to suggest alternatives for 
addressing a broad problem area. A study on the choice of interventions 
to control air pollutants found that in South Africa the most cost-
effective interventions are those that focus on the household level, 
e.g. training people to place firewood on top of, rather than under, 
the coal in a fireplace and encouraging the insulation of ceilings.24  In 
contrast, government tends to focus on industrial pollutants: these 
tend to be cost-ineffective interventions. 
A study showing the value of re-introducing residual spraying 
of households to control malaria is influencing practice in African 
countries that previously focused exclusively on insecticide-treated 
bed nets.7 In Mozambique it was found that residual spraying 
was relatively inexpensive and reduced malaria-related suffering, 
including a reduction of malaria rates in neighbouring South 
Africa.25
CEA therefore encourages government to choose explicitly 
between different courses of action. Such trade-offs are highlighted 
by a study that considered the costs and affordability of scaling up 
ART and revealed how extending second-line treatment to patients 
has reduced the chance of meeting the goal of universal access to 
first-line treatment.22
Internationally, the need to make explicit equity and efficiency 
trade-offs between different choices, and to incorporate affordability 
concerns, has led to a third application of CEA analysis in population-
level priority setting, namely the development of ‘packages’ of 
care to define what services the state aspires (or guarantees) to fund 
and provide to its population (either directly or indirectly through 
insurance mechanisms and contracted providers). Developing such 
‘essential health care packages’ hinges on, first, identifying health 
problems that are responsible for the highest burden of disease and, 
second, identifying highly cost-effective conditions that address these 
problems. Thus scarce resources are made to go further, significantly 
impacting on population health. 
Under apartheid South Africa did not have good data on the 
burden of disease, even at the national level and even for mortality. 
Attempts to provide more reliable estimates of the disease burden of 
poor and marginalised communities began in the early 1990s and 
informed policy around the time of the first democratic elections.26 
Improving the quality of mortality data since the mid-1990s enabled 
more extensive analyses of mortality data, although problems remain 
in estimating the burden accurately for certain conditions and 
communities. 
The 2000 national burden of disease study for the first time 
provided disaggregated data by province.27 The Western Cape has 
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done a more detailed analysis of the burden of disease within the 
province.28-29 This study prioritised the most important health 
problems and risk factors and stimulated discussion on priority 
interventions within the provincial Department of Health. This 
is perhaps the first example of burden of disease information 
being channelled into a detailed planning process, especially at the 
provincial level. The study was especially useful in highlighting 
neglected areas, such as the importance of motor vehicle accidents 
in young children, violence against older children, and alcohol abuse 
(personal communication with sub-district manager in the Western 
Cape Department of Health). 
A more detailed burden of disease exercise identifying the burden 
associated with key risk factors and suggesting key interventions 
was conducted in 2007. Key interventions were derived through 
examining international and local evidence (on cost-effectiveness, 
among other things) and through consulting with experts.30-44 
Importantly, these interventions are not simply biomedical in nature, 
but extend to interventions aimed at health promotion, social change 
and development.31
Given remaining problems with the quality of national mortality 
data, and difficulties in obtaining disaggregated data on the disease 
burden faced by poor and marginalised communities, alternative 
strategies have emerged in South Africa. For example, the Agincourt 
Health and Demographic Surveillance System, located in a remote 
rural area in north-eastern South Africa, has provided more 
detailed and accurate data that deepen, and sometimes overturn, 
understanding developed on the basis of national datasets (e.g. the 
TB burden is double the original estimate).45
Several South African exercises also inform the other side of 
package development, namely prioritising interventions that address 
the main burden of disease. Generally these do not rely heavily on 
cost-effectiveness information but include an analysis of cost and 
affordability. 
The Need Norms Project assembled a primary care package 
based on empirical evidence from ‘best practice’ sites and norms 
developed through consultation with experts: service targets 
developed through this process were modified by the application 
of specific principles, including affordability and cost-effectiveness 
considerations, especially with respect to targeting and the frequency 
of interventions.46 Modified data from this project were used to 
develop an official primary health care package for the post-apartheid 
government.47 The package was based on the principles of equity 
and comprehensiveness and aimed to influence the organisation 
of services in the direction of patient-centeredness.48 It was also 
affordable, costing less than the actual per capita expenditure on 
primary care as estimated through a national health accounts 
exercise.49 
The primary health care package was followed by the development 
of packages for district, regional and tertiary hospitals.50-52  These 
mainly arose out of wide-ranging consultation with experts (although 
the primary and district hospital packages were also informed by 
empirical costing studies). Presumably cost-effectiveness information 
would have influenced expert advice, but it was not used as the main 
instrument for making choices between different components of the 
package. The same holds true for the legislated ‘Prescribed Minimum 
Benefits’ that must be provided by South African medical schemes.
The use of CEA in ranking interventions for inclusion in a 
government-sanctioned package has limitations.49,53-54 For example, 
studies that compare a range of interventions across the spectrum of 
health conditions are extremely complex: data and methodological 
failings can skew findings, while it is difficult to know how to rank 
interventions that have not yet been researched. Listing individual 
interventions can also unwittingly encourage verticalisation 
of programmes. A focus on cost-effectiveness can also detract 
from dealing with the underlying structural problems that cause 
inefficiencies and indeed ill-health. In South Africa, these limitations 
raise concerns about how a package determined on the basis of 
cost-effectiveness would impact on equity and the achievement of a 
functional district health system.
Partly for these reasons, the application of essential health packages 
has had mixed results internationally.49,55 To focus on one of the 
more positive and well-documented examples, the Tanzanian Health 
Interventions Project was able to bring about a 40% reduction in 
mortality in demonstration districts; however, this impact resulted 
from a range of interventions and not just the application of 
cost-effectiveness information, and involved considerable technical 
support at the district level. 
Conclusions
Some capacity to undertake costing and CEA in South Africa already 
exists. CEA information has already influenced clinical decision-
making and policy. The following are possibilities offered by CEA and 
burden of disease estimates to contribute further to decision-making 
in South Africa: 
1.    Promotion of dialogue on health and health care priorities as well 
as affordability.
2.    Advocacy against interventions that are clearly cost-ineffective 
and unaffordable (especially at central hospital level).
3.    Advocacy for interventions that strengthen the district health 
system (because of the highly cost-effective nature of primary and 
district hospital care), including motivation for increased funding 
from Treasury.
4.    Advocacy for acceptable pricing of drugs and vaccines.
5.    Assessment of innovative new interventions, including those for 
emerging conditions.
6.    Identifying clusters of interventions that can enhance the shared 
use of inputs, reduce costs to patients, achieve synergy between 
interventions, reach related individuals, and screen patients at the 
primary level to increase efficiency of referral.
7.    Clarification of the roles of different providers and levels of care.
In making this contribution, CEA (and burden of disease estimates) 
must continue to be careful to:
1.    Incorporate equity as an up-front concern through strategies 
such as disaggregating data according to socio-economic groups 
and gender, clearly identifying gaps in data which make burden 
of disease and cost-effectiveness estimates unreliable, taking into 
account societal costs (especially catastrophic expenditure by 
households) and acknowledging that there may be occasions were 
equity concerns over-ride cost-effectiveness. 
2.    Explore interventions, including clustering of services, that reduce 
fragmentation (and build features that improve quality, encourage 
trust in the health system and respect patient dignity).
3.    Adjust international experience to the local context. 
4.    Evaluate the impact of cost-effectiveness-based decisions on 
resource allocation patterns.
International experience shows that priority setting based on 
cost-effectiveness and burden of disease estimates is essentially a 
political rather than a technical exercise and therefore ‘political and 
institutional processes need to be engaged’.55
Apart from these roles for CEA, improving the performance of 
the health system is only partly about improving technical efficiency. 
The public health system is under-resourced, there is a shortage 
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of skilled staff, and the system suffers from poor management and 
low staff morale. Furthermore, health care resources are distributed 
inequitably across the socio-economic gradient. These features may 
have more to do with the failure of the health system to address health 
care priorities than inappropriate choices around specific health care 
interventions.
This paper is based on a longer report that was funded by the Fogarty 
International Center at the US NIH and the Bill and Melinda Gates 
Foundation as part of the launch of the PRICELESS SA initiative, August 
2009. 
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Appendix A. South African studies that look at the burden of disease and costs and benefits of interventions 
Category Main findings and policy relevance
Assessment of the burden of disease •    Analyses of mortality data have been conducted since the early 1990s. There have been 
some improvements in the quality of mortality data over this time, but studies still have 
to make extensive extrapolations based on demographic and epidemiological models. 
The most recent national burden of disease study was able, for the first time, to provide 
disaggregated data by province, as a first step in illuminating the inequalities that 
characterise South African society. The study found that all provinces face a ‘quadruple’ 
burden of disease (that is, diseases associated with poverty, non-communicable illness, 
injuries and HIV/AIDS).27
•    The Western Cape conducted its own, more detailed burden of disease study in 2007.28-29 
This study prioritised the most important health problems and risk factors and began a 
process of identifying priority interventions to address these problems.
•    In 2007, a study estimated the burden of disease in South Africa resulting from major risk 
factors. It identified the priority factors that need to be addressed and suggested a range of 
interventions based on international and local studies.30-44
•    A recent international study estimated the health and economic burden of rheumatoid 
arthritis in several countries, including South Africa.56
Assessment of when it is cost-effective for an 
individual patient to receive an intervention
•    An early study found that, in selected patients with aplastic anaemia who do not have the 
option of receiving an allogeneic bone marrow transplant, it is cost-effective to provide 
treatment with antilymphocyte globulin combined with high-dose methylprednisolone.57
•    A study assessed whether South African hypertension guidelines are cost-effective. It found 
that the strategy at that time of deciding on treatment based on a target blood pressure level 
(i.e. a single risk factor) was more costly and less effective than initiating treatment based 
on an estimation of global risk (due to a number of factors) of more than 15%. The study 
concluded that the use of the latter approach would free up substantial resources.4
•    Work has been done with respect to the CD4 count at which patients should receive ART, 
suggesting that initiating treatment before the CD4 counts fall to 200 is more cost-effective.2
Assessment of whether an intervention for an 
emerging condition is sufficiently cost-effective 
to warrant a government programme
•    A study in the late 1980s estimated the costs ensuing from smoking (i.e. lost productivity 
due to premature death and the costs of health care) and found that these and future costs 
outweighed any economic benefit the industry may have brought to South Africa.14
•    A study comparing the costs and benefits of introducing a Haemophilus influenzae type B 
vaccine to a birth cohort in Cape Town found that the programme would have generated 
savings of between R2.5 milllion and R3.5 million in 1995 prices.58
•    A study in the mid-1990s highlighted the economic burden resulting from cardiovascular 
disease in South Africa, noting that it is sufficiently high to warrant a population-based 
strategy to diagnose and treat conditions cost-effectively.59
•    In 2000, a South African study found that a national programme preventing a third of 
expected paediatric HIV infections would be relatively cheap per capita and, in terms of 
cost-effectiveness, would compare well with other public health and clinical interventions 
in middle-income countries.17 A subsequent, more detailed cost-effectiveness study in 2002 
found that each HIV-positive child costs the South African government more in terms of 
health and welfare than it would to reduce mother-to-child transmission of HIV through 
the use of nevirapine.18
•    Subsequently, cost-effectiveness studies began to look at the cost-effectiveness and 
affordability of antiretroviral treatment for HIV-infected patients in general. One very 
detailed cost-effectiveness study confirmed that treatment is cost-effective.2 Another study 
found that antiretroviral treatment leads to overall health service savings as it reduces the 
need for clinical care: this cost-saving increases as drug prices come down.19
•    Another study estimated the costs of extending antiretroviral therapy to health care workers 
in KwaZulu-Natal.20 It motivated that these costs would be moderate and that benefits 
would be reaped in terms of reducing absenteeism and alleviating future staff shortages.
•    Qualitative work has already been conducted around the introduction of a human 
papillomavirus vaccine to prevent cervical cancer.23 This, together with a cost-effectiveness 
analysis (which has not yet been published), has led the Department of Health to consider 
seriously the option of introducing the vaccine into its immunisation programme (personal 
communication with Edina Sinanovic and Di McIntyre, Health Economics Unit, University 
of Cape Town). 
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Assessment of the affordability of scaling up an 
intervention
•    A tool was developed to assess resource requirements for scaling up mental health services for 
children and adolescents, at different levels of coverage.60 The study showed a substantial shortfall 
in current services.
•    The study described above on the introduction of a human papillomavirus vaccine to prevent 
cervical cancer, also indicates the vaccine price at which it will become cost-effective to introduce 
the vaccine. This can assist the government in negotiating a reduction in the price of the vaccine 
(personal communication with Di McIntyre, Health Economics Unit, University of Cape Town).
Evaluation of interventions •    In 2003 South Africa initiated a programme to fortify staple foods with folic acid. A 
subsequent study found a decline of around a third in neural tube defects in new births. 
The study estimated that the medical intervention costs that were averted by folic acid 
supplementation amounted to 30 times the cost of the supplementation programme.61
•     A study looking at the costs of treating patients in secondary hospitals around the time of 
antiretroviral initiation showed that the burden on these hospitals was significant, resulting 
in the need for government to accommodate these costs in its plans.62
Comparison of alternative interventions or 
different models of delivery
•    The costs and benefits of mobile versus fixed-clinic services were analysed to assist in improving 
the efficiency of primary health care.63
•    A study compared the cost-effectiveness of residual house-spraying versus insecticide-treated 
bed nets in the control of malaria in KwaZulu-Natal. It found bed nets to be more cost-effective, 
despite their higher costs, but cautioned that close monitoring of the use of nets was necessary to 
assess if cost-effectiveness would change over time.64
•    An early study looking at ART provision explored different scenarios for delivering treatment 
and suggested that treatment could be cost-effective and affordable, depending on different 
policy choices.65 
•    A study found that although a course of sulfadoxine-pyrimethamine is much more expensive 
than chloroquine for malaria treatment, it is almost 5 times more cost-effective.66 A subsequent 
study found that replacing monotherapy (with sulphadoxine-pyrimethamine) with dual therapy 
(i.e. artemether-lumefantrine) in KwaZulu-Natal led to a decline of around a third and half of the 
outpatient cases and inpatient admissions, respectively.1 Although dual therapy is considerably 
more expensive, its better cure rate led to a saving of around $200 000 in 2002 alone. However, 
this was in a context of low efficacy of monotherapy and good vector control.
•    In 1997, an economic analysis of community-based directly observed therapy for tuberculosis in 
Hlabisa, KwaZulu-Natal, found that costs to both patients and the health service were reduced 
considerably by using community observation.67 This form of care was also cost-effective. A 
subsequent study that looked at outcomes and costs of TB treatment in Cape Town compared 
clinic-based care with clinic-based care supported by observation by community health workers. 
The study, which included costs from a societal perspective, found that community involvement 
improved the affordability and cost-effectiveness of treatment.6 Another study noted that 
community health workers increase the return rate of women who miss their scheduled visits 
for cervical screening and that these benefits should be incorporated in future cost-effectiveness 
analyses aimed at policy decisions about cervical cancer screening.68
•    Another study found that there is a strong economic case for expanding public-private partnerships 
in TB treatment, concluding that, if these partnerships are tailored to target groups and supported 
by the public sector, scaling up would be much more affordable than public models of delivery 
(partly because some of these partnerships are work-based and thus close to the patient).69
•    A cost-effectiveness study found that the ‘ProTEST package’ of combined TB and HIV 
interventions in the primary care setting in Cape Town was cost-saving.8 The prevention of TB 
cost less than previous estimates because of the linkage of prevention and care interventions for 
both TB and HIV. Voluntary counselling and testing was also found to be less expensive than 
reported in other African studies.
•    A study comparing the costs and benefits of different interventions to control air pollutants 
found that the most cost-effective interventions are those that focus on the household 
level.24 By way of contrast, government focuses on industrial pollutants, with most proposed 
industrial interventions failing the cost-benefit test. Household interventions include low-
cost interventions such as training householders to place firewood on top of the coal in a 
fireplace and encouraging the insulation of ceilings. The control of pollution from vehicle 
fuels was the next most important set of interventions.
•    A study investigated the different outcomes and costs of different models for antiretroviral 
delivery. The models were an urban public hospital, a programme that contracts private 
general practitioners, a rural non-governmental AIDS clinic, and a peri-urban non-
governmental primary care clinic.70
•    A study that determined the cost-effectiveness of cervical cancer screening strategies that 
involved human papillomavirus testing found that testing is cost-effective.71 The study 
presented the incremental costs of different combinations of screening strategies.
